Premium
CCND1‐BCL2 Gene Network: A direct target of Amifostine in human acute megakaryocytic leukemia cells
Author(s) -
Zhang Feng,
Yang Bo,
Zhang Kailiang,
Hou MeiLing,
Lu Xuechun,
Li YuXin
Publication year - 2017
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12889
Subject(s) - amifostine , cancer research , apoptosis , leukemia , cell cycle , gene , acute leukemia , chemistry , biology , medicine , immunology , radiation therapy , biochemistry
Amifostine, 2‐(3‐aminopropyl) aminoethyl phosphorothioate, is a broad‐spectrum cytoprotective agent used to treat nuclear radiation and chemical weapon injuries. Recently, amifostine has been shown to have a profound biological influence on tumor cells. To examine the effects and mechanisms underlying the effects of amifostine on human acute megakaryocytic leukemia, we evaluated the efficacy of amifostine against Dami cells and observed a cell cycle arrest in G 2 /M phase. Amifostine treatment also induced cell apoptosis of Dami cells which corresponds to formal studies. Through whole‐genome microarray and bioinformatics analyses, we found that amifostine affected the gene expression of CCND 1 , BCL 2 , and CASP 3 which revealed the mechanism amifostine acted on Dami cells. Thus, CCND 1‐ BCL 2 Gene Network is predicted to be a direct target of amifostine treating human acute megakaryocytic leukemia, which may provide a novel potential target for the therapy of several subtypes of human AML .